Clinical Trials Logo

Tumor, Solid clinical trials

View clinical trials related to Tumor, Solid.

Filter by:

NCT ID: NCT04840394 Active, not recruiting - Tumor, Solid Clinical Trials

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

NCT ID: NCT04819373 Completed - Tumor, Solid Clinical Trials

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Start date: August 30, 2021
Phase: Phase 2
Study type: Interventional

BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.

NCT ID: NCT04788147 Completed - Cancer Clinical Trials

Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)

BIOGUIDE-X
Start date: March 26, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the performance and safety of Biology-Guided Radiotherapy (BgRT) using the RefleXion Medical Radiotherapy System (RMRS) via optimizing F18-Fluorodeoxyglucose (FDG) dosing, assessing the performance of the Positron Emission Tomography (PET) imaging subsystem for BgRT treatment planning and delivery, including its role as an interlock, and validating the dose delivery performance of the end-to-end BgRT workflow.

NCT ID: NCT04750772 Recruiting - Colorectal Cancer Clinical Trials

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

To evaluate the normal physiological distribution of positron nuclide labeled DOTA-FAPI PET/CT in human body and its diagnostic efficiency for colorectal cancers

NCT ID: NCT04723810 Not yet recruiting - Tumor, Solid Clinical Trials

TumorGlow Intraoperative Molecular Imaging (IMI)

Start date: October 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.

NCT ID: NCT04717674 Recruiting - Cancer Clinical Trials

[18F]FPIA PET/CT Imaging in Patients With Solid Tumours

[18F]FPIA
Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

The study will be a phase 2, open-label study in patients with solid tumours to explore the relationship between short-chain fatty acid uptake using [18F]FPIA PET/CT and tumour proliferation

NCT ID: NCT04640246 Recruiting - Cancer Clinical Trials

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Start date: January 25, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.

NCT ID: NCT04628234 Completed - Clinical trials for Hematologic Malignancy

Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT)

RESPECT
Start date: July 4, 2020
Phase:
Study type: Observational

This is a non randomized, monocentric, descriptive, transversal and prospective study. The purpose of this study is to assess the compliance with patient expressed choice regarding subsequent care and death -if occured- site (at hospital or at home) after hospitalisation for terminally ill patients with an onco-hematologic solid tumor in palliative care and to identify reasons for potential non-compliance.

NCT ID: NCT04528836 Active, not recruiting - Tumor, Solid Clinical Trials

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Start date: November 12, 2020
Phase: Phase 1
Study type: Interventional

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.

NCT ID: NCT04443088 Recruiting - Cancer Clinical Trials

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

KEYNOTE-E12
Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.